Reed Siemieniuk
Bsc (University of Waterloo)
MD (McMaster University)
PhD (McMaster University
Dr. Siemieniuk joined the Faculty at McMaster in July 2021 as an Assistant Professor in the Departments of Health Research Methods, Evidence and Impact and the Department of Medicine
Training
Dr. Siemieniuk completed his B.Sc. at the University of Waterloo in 2009, his MD at McMaster in 2012, his internal medicine training at the University of Toronto in 2019, and his PhD (during which he was awarded a Banting and Best Graduate Scholarship and subsequently a Vanier Canada Graduate Scholarship) in Health Research Methods at McMaster in 2020.
Medical Practice
Dr. Siemieniuk is an attending physician in the inpatient general internal clinical teaching unit at the Hamilton General Hospital
Research
During an extraordinary PhD Dr. Siemieniuk established himself as a world leading systematic review and guideline methodologist. He was a co-founder of BMJ Rapid Recommendations and continues as a steering group member. The BMJ Rapid Recommendations are a collaborative project between the MAGIC Research and Innovation group and The BMJ, which moves new practice-changing evidence to the clinic sooner through trustworthy clinical practice recommendations. BMJ Rapid Recommendations represent a growing organization, whose model is being adopted by a growing number of major guideline societies.
In his leading role with BMJ Rapid Recommendations Dr. Siemieniuk has published 19 papers in the BMJ including 6 as first author and two as senior author.
Also during his PhD, Dr. Siemieniuk has taken on the role of a senior methodologist with the Infectious Disease Society of America, playing a key part in a number of their clinical practice guidelines.
In his latest and perhaps most impressive work, Dr. Siemieniuk conceived the idea, at the beginning of the pandemic, of a living network meta-analysis of randomized trials of drug and immune interventions for COVID-19. Dr. Siemieniuk assembled a team of over 60 methodologists, statisticians, and clinical experts. He created sub-teams, each with its own leader, to deal with identifying the trials, determining their eligibility, abstracting the data, assessing risk of bias, and conducting the network meta-analysis including GRADE rating of certainty of evidence. The NMA addressing drug treatments, published in the BMJ, has an altmetric score of over 200,000. The team has also published an NMA of drugs for prevention of COVID-19 and the BMJ and will soon be publishing their immune therapy NMA.
Dr. Siemieniuk is also a key player in the WHO guidelines for drug and immune prevention and treatment of COVID-19. The living NMA informs the WHO guidelines. This work has established Dr. Siemieniuk as a leading researcher in the worldwide evidence synthesis and guideline efforts directed at the prevention and treatment of COVID-19.
